Personalized anti-cancer therapy, maximizing immunogenicity.

Personalized anticancer vaccines, available off-the-shelf, anywhere.

Frame Therapeutics is dedicated to transforming the treatment of cancer by directing the immune system towards Frame neoantigens. We are developing personalized cancer immunotherapies, which are designed based on the Frame neoantigens uniquely encoded by the genome of each patient's tumor.

Our technology is based on the combination of two recent breakthrough developments in genomics and immunotherapy. First, next-generation DNA sequencing technology makes it possible to rapidly read the genomes of both tumor and healthy cells and identify mutations that may give rise to neoantigens. This gives the opportunity to create personalized medicines that are based on the tumor DNA sequence of the patients. 

Second, new developments in immunology have made immunotherapy of cancer a new treatment option, in addition to the three classic pillars of oncological treatment: surgery, radiation and chemotherapy. Analysis of mutations across thousands of tumors helped us identify the best neoantigens to include in vaccines which can be prepared and stored on the shelf and made available for patients and their doctors on demand.   

Our approach

We develop a Frame-based personalized immunotherapy approach, which is applicable to almost all patients with cancer. Our Frame-based treatments cover the bulk of the antigenicity of tumor, thereby providing maximum therapeutic benefit.

News update

funding

May 6, 2020

Consortium Frame Therapeutics, Amsterdam UMC and UMC Groningen receives ERDF grant to develop cancer vaccines

   

At Frame Therapy, we are committed to progressing the field of immunotherapy, with a goal to eradicate cancer by initially developing anti-cancer vaccines that focus on the unique and individual nature of a patient’s tumor. Our dynamic team combines novel science with focus on team work, and we are looking for passionate, innovative people to join us.